Plasma concentrations of oral oxycodone are greatly increased in the elderly

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 4, 2008, Pages 462-467

  Liukas, A ^a   Kuusniemi, K ^a   Aantaa, R ^a   Virolainen, P ^a   Neuvonen, M ^b   Neuvonen, P J ^b   Olkkola, K T ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450 2D6; DRUG METABOLITE; ITRACONAZOLE; OXYCODONE; OXYMORPHONE; OXYNORM; PAROXETINE; RIFAMPICIN; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CYP2D6 GENE; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; GENE; GENOTYPE; HUMAN; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; AREA UNDER CURVE; FEMALE; HUMANS; MALE; MIDDLE AGED; OXYCODONE;

EID: 56449127739     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.64     Document Type: Article

References (25)

1. Rischitelli, D.G. & Karbowicz, S.H. Safety and efficacy of controlled-release oxycodone: a systematic literature review. Pharmacotherapy 22, 898-904 (2002).
2. Paulozzi, L.J. Opioid analgesic involvement in drug abuse deaths in American metropolitan areas. Am. J. Public Health 96, 1755-1757 (2006).
3. Pöyhiä, R., Olkkola, K.T., Seppälä, T. & Kalso, E. The pharmacokinetics of oxycodone after intravenous injection in adults. Br. J. Clin. Pharmacol. 32, 516-518 (1991).
4. Pöyhiä, R., Seppälä, T., Olkkola, K.T. & Kalso, E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br. J. Clin. Pharmacol. 33, 617-621 (1992).
5. Leow, K.P., Smith, M.T., Watt, J.A., Williams, B.E. & Cramond, T. Comparative oxycodone pharmacokinetics in humans after intravenous, oral and rectal administration. Ther. Drug. Monit. 14, 479-484 (1992).
6. Leow, K.P., Smith, M.T., Williams, B.E. & Cramond, T. Single dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin. Pharmacol. Ther. 52, 487-495 (1992).
7. Lalovic, B., Kharasch, E., Hoffer, C., Risler, L., Liu-Chen, L. & Shen, D.D. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites. Clin. Pharmacol. Ther. 79, 461-479 (2006).
8. El-Tahtawy, A., Kokki, H. & Reidenberg, B.E. Population pharmacokinetics of oxycodone in children 6 months to 7 years old. J. Clin. Pharmacol. 46, 433-442 (2006).
9. Kokki, H., Rasanen, I., Reinikainen, M., Suhonen, P., Vanamo, K. & Ojanperä, I. Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. Clin. Pharmacokinet. 43, 613-622 (2004).
10. Olkkola, K.T., Hamunen, K., Seppälä, T. & Maunuksela, E.-L. Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children. Br. J. Clin. Pharmacol. 38, 71-76 (1994).
11. Pokela, M.-L., Anttila, E., Seppälä, T. & Olkkola, K.T. Marked variation in oxycodone pharmacokinetics in infants. Pediatr. Anaesth. 15, 560-565 (2005).
12. Schwartz, J.B. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin. Pharmacol. Ther. 82, 87-96 (2007).
13. O'Connell, M.B. et al. Effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women. J. Clin. Pharmacol. 46, 1299-1307 (2006).
14. Ohara, K., Tanabu, S., Ishibashi, K., Ikemoto, K., Yoshida, K. & Shibuya, H. Effects of age and the CYP2D6*10 allele on the plasma haloperidol concentration/dose ratio. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 347-350 (2003).
15. Lalovic, B., Phillips, B., Risler, L.L., Howald, W. & Shen, D.D. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug. Metab. Dispos. 32, 447-454 (2004).
16. Eichelbaum, M. & Gross, A.S. The genetic polymorphism of debrisoquine/sparteine metabolism: clinical aspects. Pharmacol. Ther. 46, 377-394 (1990).
17. Bertz, R.J. & Granneman, G.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32, 210-258 (1997).
18. Lee, H.K. et al. Negative urine opioid screening caused by rifampin-mediated induction of oxycodone hepatic metabolism. Clin. Chim. Acta 367, 196-200 (2006).
19. von Moltke, L.L., Greenblatt, D.J., Duan, S.X., Harmatz, J.S., Wright, C.E. & Shader, R.I. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J. Clin. Psychopharmacol. 16,104-112 (1996).
20. Olkkola, K.T., Backman, J.T. & Neuvonen, P.J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 55, 481-485 (1994).
21. Bertelsen, K.M., Venkatakrishnan, K., Von Moltke, L.L., Obach, R.S. & Greenblatt, D.J. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug. Metab. Dispos. 31, 289-293 (2003).
22. Heiskanen, T., Olkkola, K.T. & Kalso, E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin. Pharmacol. Ther. 64, 603-611 (1998).
23. Kennedy, J.M. & Riji, A.M. Effects of surgery on the pharmacokinetic parameters of drugs. Clin. Pharmacokinet. 35, 293-312 (1998).
24. Nimmo, W.S., Heading, R.C., Wilson, J., Tothill, P. & Prescott, L.F. Inhibition of gastric emptying and drug absorption by narcotic analgesics. Brit. J. Clin. Pharmacol. 2, 509-513 (1975).
25. Sistonen, J., Fuselli, S., Levo, A. & Sajantila, A. CYP2D6 genotyping by a multiplex primer extension reaction. Clin. Chem. 51, 1291-1295 (2005).